Perceptive Advisors LLC Bridge Bio Pharma, Inc. Transaction History

Perceptive Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$23.0 - $31.04 $4.52 Million - $6.11 Million	-196,687 Reduced 13.93%	1,215,346 $30.8 Million
Q1 2024 May 15, 2024	SELL	$27.35 - $40.45 $9.21 Million - $13.6 Million	-336,900 Reduced 19.26%	1,412,033 $43.7 Million
Q2 2023 Aug 14, 2023	SELL	$13.29 - $18.01 $2.1 Million - $2.85 Million	-158,100 Reduced 8.29%	1,748,933 $30.1 Million
Q1 2023 May 15, 2023	BUY	$7.17 - $18.55 $1.51 Million - $3.9 Million	210,000 Added 12.37%	1,907,033 $31.6 Million
Q2 2022 Aug 15, 2022	SELL	$5.21 - $12.14 $11.2 Million - $26 Million	-2,142,347 Reduced 55.8%	1,697,033 $15.4 Million
Q1 2022 May 16, 2022	SELL	$7.34 - $17.16 $24.1 Million - $56.4 Million	-3,289,375 Reduced 46.14%	3,839,380 $39 Million
Q4 2021 Feb 14, 2022	SELL	$11.38 - $53.41 $7.15 Million - $33.6 Million	-628,173 Reduced 8.1%	7,128,755 $119 Million
Q1 2021 May 17, 2021	BUY	$55.47 - $72.35 $58.3 Million - $76 Million	1,050,660 Added 15.67%	7,756,928 $478 Million
Q2 2019 Aug 14, 2019	BUY	$26.97 - $27.55 $181 Million - $185 Million	6,706,268 New	6,706,268 $181 Million

290

170M

10.4M

2.37M

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $4.23B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.